Type 1 diabetes (T1D), a chronic autoimmune disease, continues to pose significant challenges due to the immune system’s relentless destruction of pancreatic islets—clusters of cells responsible for insulin production and crucial regulation of blood glucose levels. Insulin, a vital peptide hormone, orchestrates cellular glucose uptake to maintain metabolic homeostasis. The loss of insulin-producing beta cells in T1D patients precipitates lifelong dependence on exogenous insulin therapies, which, despite their lifesaving role, are incapable of fully mimicking natural pancreatic function. Emerging regenerative strategies, notably islet transplantation, have offered promising avenues toward restoring endogenous insulin production, yet have been hampered by the need for systemic immunosuppression to prevent graft rejection—bringing with it deleterious side effects and increased susceptibility to infections and malignancies.
In a groundbreaking development, researchers from the University of Missouri School of Medicine have pioneered an innovative approach to islet transplantation that circumvents the necessity for chronic immunosuppressive regimens. This novel strategy hinges on the precise bioengineering of donor islets through the covalent attachment of two immune-modulatory molecules: thrombomodulin and CD47. Thrombomodulin, an endothelial cell surface glycoprotein, is known for its anti-inflammatory and anticoagulant properties. It inhibits the activation of the complement cascade and attenuates detrimental inflammatory responses that typically lead to early islet destruction post-transplant. Concurrently, CD47 serves as a “don’t eat me” signal by engaging signal regulatory protein alpha (SIRPα) receptors on macrophages and other immune effector cells, effectively signaling these cells to inhibit phagocytosis and cytotoxic attacks against the graft.
The synergy of thrombomodulin and CD47 integration onto islet surfaces has demonstrated remarkable efficacy in preclinical animal models. The researchers reported that over 72% of recipients transplanted with these co-engineered islets exhibited normalization of blood glucose levels without exogenous insulin administration—a critical milestone indicating functional restoration of endogenous insulin secretion in response to physiological glucose stimuli. This metabolic restoration attests to the bioengineered islets’ ability to maintain glucose sensing and insulin secretory functions, highlighting their clinical potential to transcend the limitations of current insulin therapy regimes.
Significantly, this bioengineering approach offers targeted immune evasion, reducing systemic exposure to immunosuppressive drugs and thereby mitigating associated risks such as nephrotoxicity, hepatotoxicity, and compromised host immunity. By localizing immune modulation to the transplant microenvironment, the transplanted islets evade innate and adaptive immune responses, extending graft survival and functional longevity. The technique exemplifies precision medicine at the cellular interface, leveraging molecular cues to harmonize transplanted tissue with the host immune milieu.
Study lead, Dr. Haval Shirwan, emphasized the transformative promise of this method: “Traditional immunosuppressants systemically weaken the host immune defense, imposing significant side effect burdens. Our approach shields the islets directly, creating a molecular armor that allows transplanted cells to blend seamlessly without evoking immune hostility.” Shirwan’s insights reflect a paradigm shift towards localized immune modulation, which could redefine the therapeutic landscape for autoimmune diseases beyond T1D.
Dr. Esma Yolcu, co-author and principal investigator in pediatric immunology, elaborated on the mechanistic basis: “Thrombomodulin attenuates deleterious inflammation by modulating coagulation and complement pathways, which are key contributors to early graft loss. CD47 operates as a critical immune checkpoint ligand, inhibiting phagocytosis by macrophages and dendritic cells. Together, they synergize to create an immunological ‘cloak’ that significantly boosts islet survival compared to the application of either molecule alone.” These findings underline the necessity of a combinatorial approach in immune engineering for transplant tolerance.
Importantly, the preclinical studies were conducted in allogeneic recipients, a model mimicking the genetic disparity between donor and recipient that typically precipitates transplant rejection. The sustained graft viability and functional insulin output observed in these models, without chronic immunosuppressant administration, forecast promising translational potential. While the experiments utilized animal subjects to establish proof-of-concept, the methodology’s translational trajectory towards human clinical trials is eagerly anticipated.
The implications of this research extend far beyond T1D management. By refining the interface between transplanted tissues and the immune system, this technology paves the way for advancements in bioengineered organ and cell therapies, fundamentally reshaping regenerative medicine. The selective modification of donor cells to skirt immune detection represents an elegant solution to one of transplantation medicine’s most intractable problems—immune rejection—without compromising systemic immune competence.
Currently, approximately 2 million individuals in the United States alone live with T1D, a population that is projected to expand as incidence rates climb globally. The burden of lifelong insulin dependence, frequent glycemic monitoring, and risk of hypoglycemic events underscore the urgent need for innovative disease-modifying therapies. This compelling research underscores the feasibility of developing transplantation-based cures that bypass the systemic toxicities of immunosuppressive drugs, promising enhanced quality of life and reduced long-term complications for patients.
Future studies will need to rigorously evaluate the safety profile and efficacy of this islet-engineering platform in human subjects. Key translational hurdles include scalable manufacturing of engineered islets, ensuring durable expression or retention of immune-regulatory molecules, and comprehensive immunological assessments within human immune systems’ complexity. However, the foundational science detailed in this study constitutes a milestone, demonstrating the concept’s viability and heralding a new dawn in the quest to cure autoimmune diabetes.
The study, titled “Islets co-engineered with thrombomodulin and CD47 achieve sustained survival in allogeneic recipients without chronic immunosuppression,” was published in JCI Insight. It represents a collaborative effort among molecular microbiologists, immunologists, and pediatric researchers who collectively leveraged cutting-edge bioengineering and immunological principles to overcome longstanding obstacles in islet transplantation.
This research exemplifies the confluence of molecular immunology, bioengineering, and clinical innovation, underscoring how understanding and manipulating immune checkpoints and inflammatory cascades at the cellular level can catalyze therapeutic breakthroughs. By harnessing nature’s own regulatory molecules, the investigators have established a promising pathway toward durable islet graft survival, potentially obviating the need for life-altering insulin therapy in T1D.
As this research progresses toward clinical validation, it also opens broader dialogues on tailoring immune evasion mechanisms for a spectrum of cell and tissue transplants, illuminating the future of precision immunotherapy in regenerative medicine. The fusion of molecular engineering and immunomodulation may very well transform autoimmune disease management and organ transplantation, with the promise of restoring physiological function with minimal adverse effects.
Subject of Research: Animals
Article Title: Islets co-engineered with thrombomodulin and CD47 achieve sustained survival in allogeneic recipients without chronic immunosuppression
News Publication Date: 17-Mar-2026
Web References: http://dx.doi.org/10.1172/jci.insight.200686
Keywords: Type 1 diabetes, Islet transplantation, Autoimmune disorders, Pancreas, Islets of Langerhans, Insulin, Immunomodulation, Thrombomodulin, CD47, Immune evasion, Regenerative medicine, Immunosuppressant alternative
